Journal: Cancer Cell International

Article Title: SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness

doi: 10.1186/s12935-021-02056-x

Figure Lengend Snippet: SHP2 facilitates the CXCL8 secretion of EGFR T790M mutant LUAD. A Differentially expressed mRNA in inhibited, over-expressed and parental PC9GR cells in plot of secreted signaling molecule, a subset of 32 significant genes were identified with an FDR of < 0.05. B mRNA expression of CXCL8 and IL-6 genes showed significant diversity among the three groups, while TGF-β1 mRNA was not significantly altered. Meanwhile the correlation analysis implied a significant correlation coefficient of r = 0.9253 between CXCL8 and SHP2, the relationship of IL-6 and SHP2 was conferred a r = 0.8501. For NGS data analysis, three replicates for each biological group were included in the analysis. C The concentration of CXCL8 in the culture medium of SHP2 over-expressing PC9GRcells was significantly higher than that of parental cells, while the CXCL8 in the supernatant of SHP2 inhibited PC9GR cells was significantly reduced. D Activated ERK, AKT and RelA/p65 were significantly up-regulated in SHP2 over-expressing cells than parental cells, and down-regulated in SHP2 knock-down cells. Each experiment was repeated 3 times

Article Snippet: SHP2 inhibitor (SHP099, Cat#: HY-100,388), recombinant human CXCL8 (Cat#: HY-P7224), CXCR2 inhibitor (Danirixin, Cat#:HY-19,768), CXCR1/2 inhibitor (Reparixin, CAT#: HY-15,251) and Osimertinib (AZD-9291, Cat#: HY-15,772) were bought from MCE LLC.

Techniques: Mutagenesis, Expressing, Concentration Assay, Knockdown

Journal: Cancer Cell International

Article Title: SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness

doi: 10.1186/s12935-021-02056-x

Figure Lengend Snippet: SHP2 inhibition suppresses the stemness and tumorigenesis of EGFR T790M mutant LUAD by CXCL8/CXCR1 positive feedback loop. A The clones were dramatically inhibited by Danirixin or Reparixin, while exogenous CXCL8 significantly enhanced the colony formation of PC9GR. B The percentage of CSCs was reduced in the setting of CXCL8-CXCR1/2 loop blockage, and recombinant CXCL8 could reverse the CSCs proportion. C In SHP2 over-expressed panel, Danirixin and Reparixin respectively decreased the CSCs to 6.193 ± 0.875 % and 5.703 ± 0.419 % from 11.223 ± 0.738 %, however additional CXCL8 raised the CSCs to 14.040 ± 0.397 %. In SHP2 inhibited panel, Danirixin and Reparixin respectively decreased the CSCs to 1.807 ± 0.309 % and 1.970 ± 0.471 % from 3.757 ± 0.237 %, but additional CXCL8 increased the CSCs to 7.010 ± 0.920 %. D CXCL8-CXCR1/2 blockage limits the weight of SHP2 high PC9GR tumors than that of treated with DMSO, which decreased from 2.050 ± 0.184 g to 0.850 ± 0.023 g and 0.993 ± 0.070 g, and tumor weight SHP2 inhibited cells reduced from 1.576 ± 0.116 g to 0.510 ± 0.106 g and 0.474 ± 0.055 g, respectively. Each experiment was repeated 3 times

Article Snippet: SHP2 inhibitor (SHP099, Cat#: HY-100,388), recombinant human CXCL8 (Cat#: HY-P7224), CXCR2 inhibitor (Danirixin, Cat#:HY-19,768), CXCR1/2 inhibitor (Reparixin, CAT#: HY-15,251) and Osimertinib (AZD-9291, Cat#: HY-15,772) were bought from MCE LLC.

Techniques: Inhibition, Mutagenesis, Clone Assay, Recombinant

Journal: Cancer Cell International

Article Title: SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness

doi: 10.1186/s12935-021-02056-x

Figure Lengend Snippet: The role of SHP2 derived CXCL8/CXCR1 positive feedback loop in EGFR T790M mutant LUAD

Article Snippet: SHP2 inhibitor (SHP099, Cat#: HY-100,388), recombinant human CXCL8 (Cat#: HY-P7224), CXCR2 inhibitor (Danirixin, Cat#:HY-19,768), CXCR1/2 inhibitor (Reparixin, CAT#: HY-15,251) and Osimertinib (AZD-9291, Cat#: HY-15,772) were bought from MCE LLC.

Techniques: Derivative Assay, Mutagenesis

Journal: BioMed Research International

Article Title: The Role of IL-6RA in UHMWPE Promotes Proliferation in Fibro-Like Synovial Cells

doi: 10.1155/2018/3928915

Figure Lengend Snippet: UHMWPE increased the expression of mIL-6R protein. FLS cells were incubated with UHMWPE (0, 0.01, 0.1, and 1g/L) for 7 d. The expression of IL-6R protein was detected by western blotting assay.

Article Snippet: The primary antibodies included caspase-3(Abcam, USA; ab4051), cleaved-caspase-3 (Cell Signaling Technology, USA; #9661), Bax (Abcam, USA; ab182733), Bcl-2 (Abcam, USA; ab692), IL-6R (Boster, China; A01425-1), β -actin (Bioss, China; bs-0061R), and GAPDH (Abcam, USA; ab8245) at 1:500 dilutions.

Techniques: Expressing, Incubation, Western Blot

Journal: Inflammatory Bowel Diseases

Article Title: IL-6 Mediates the Intestinal Microvascular Thrombosis Associated with Experimental Colitis

doi: 10.1097/mib.0000000000000656

Figure Lengend Snippet: FIGURE 6. Effects of blockade of the alpha (IL-6Ra) and beta (gp130) subunits of the IL-6 receptor on DSS colitis-enhanced thrombus formation in colonic arterioles. *P , 0.05 compared with corresponding WT-H2O group, #compared with WT-DSS group, and +compared with WT-DSS vehicle group.

Article Snippet: Rat antimouse IL-6Ra (CD126)-blocking antibody was purchased from Angio-Proteomie (Boston, MA).

Techniques: